Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS).

Next Previous
Trial Profile

Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms PEDS
  • Sponsors Amgen

Most Recent Events

  • 04 Nov 2016 According to Amgen media release, the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL (etanercept) to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis based on the results of this trial and its open-label extension..
  • 10 Mar 2016 According to an Amgen media release, the US FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept) to treat pediatric patients with chronic severe plaque psoriasis. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 5 November 2016 for the ENBREL sBLA. The sBLA was submitted based on the results of this trial and its open-label extension.
  • 13 Sep 2010 Tolerability data from the withdrawal-retreatment period were published in the Journal of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top